MedPath
HSA Approval

OPTIZOLINE EYE DROPS 0.05%

SIN06918P

OPTIZOLINE EYE DROPS 0.05%

OPTIZOLINE EYE DROPS 0.05%

March 23, 1992

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.
Licence HolderAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

SOLUTION

OPHTHALMIC

Medical Information

S01GA02

tetryzoline

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

TETRAHYDROZOLINE HCl

0.05%

Tetryzoline

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

OPTIZOLINE EYE DROPS 0.05% - HSA Approval | MedPath